Drug Repurposing Patent Applications October-December 2024

Area of Science:

• Pharmaceutical Sciences
• Drug Discovery
• Intellectual Property

Background:

• Drug repurposing is a key strategy for developing new therapeutics.
• Recent patent filings indicate a surge in innovation in this field.
• Global interest in drug repurposing spans multiple continents and research institutions.

Purpose of the Study:

• To review significant PCT patent applications in drug repurposing published in late 2024.
• To highlight the diversity of applicants, therapeutic targets, and geographic representation.
• To showcase novel drug repurposing strategies and potential treatments.

Main Methods:

• Analysis of 17 PCT patent applications related to drug repurposing.
• Selection based on significance of innovation.
• Categorization by applicant, active agent, and geographic origin.

Main Results:

• Diverse applicants from US, China, Japan, Germany, UK, Canada, Algeria, and Iceland.
• Specific examples include entacapone for therapeutic hypothermia, sulindac for Angelman syndrome, and gliclazide for schizophrenia.
• Demonstrated potential for treating neurodevelopmental disorders and neurological conditions.

Conclusions:

• Late 2024 patent filings reveal a dynamic landscape of drug repurposing research.
• Innovation is geographically widespread, with significant contributions from various international entities.
• Identified repurposing candidates offer promising therapeutic avenues for challenging diseases.